Diethyl(3-pyridyl)borane CAS 89878-14-8 Purity >99.0% (HPLC) Abiraterone Acetate Intermediate Factory
Manufacturer Supply, High Purity, Commercial Production
Chemical Name: Diethyl(3-pyridyl)borane
CAS: 89878-14-8
| Chemical Name | Diethyl(3-pyridyl)borane |
| Synonyms | 3-(Diethylboryl)pyridine |
| CAS Number | 89878-14-8 |
| CAT Number | RF-PI674 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C9H14BN |
| Molecular Weight | 147.03 |
| Melting Point | 159.0~164.0℃ (lit.) |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White Powder |
| Infrared Spectrum | Conforms to Structure |
| Purity / Analysis Method | >99.0% (HPLC) |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.50% |
| Single Impurity | ≤0.50% |
| Total Impurities | <1.00% |
| Heavy Metals (as Pb) | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Abiraterone Acetate (CAS: 154229-18-2) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
Diethyl(3-pyridyl)borane (CAS: 89878-14-8) is an intermediate of Abiraterone Acetate (CAS: 154229-18-2). In April 2011, the United States FDA approved Abiraterone Acetate in combination with the steroid prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) for patients who were previously treated with a docetaxel containing regimen for late-stage disease. The drug, marketed under the trade name Zytiga, was originally discovered by researchers at the Cancer Research UK Centre for Cancer Therapeutics in 1990, developed by Cougar Biotechnology, and ultimately commercialized by Johnson & Johnson after its acquisition of Cougar in 2009.
